

Iuliana Vaxman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6410243/publications.pdf>

Version: 2024-02-01

51
papers

575
citations

759233
12
h-index

677142
22
g-index

51
all docs

51
docs citations

51
times ranked

928
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. <i>Nature Medicine</i> , 2021, 27, 491-503.	30.7	118
2	Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. <i>Acta Haematologica</i> , 2019, 141, 93-106.	1.4	74
3	When to Suspect a Diagnosis of Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 304-311.	1.4	41
4	Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2015, 50, 706-714.	2.4	29
5	Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature. <i>Hematological Oncology</i> , 2017, 35, 591-598.	1.7	29
6	New developments in diagnosis, risk assessment and management in systemic amyloidosis. <i>Blood Reviews</i> , 2020, 40, 100636.	5.7	28
7	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	6.2	28
8	Venetoclax for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2018, 11, 915-920.	2.2	27
9	FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. <i>Hematological Oncology</i> , 2019, 37, 168-175.	1.7	25
10	Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. <i>Clinical Microbiology and Infection</i> , 2018, 24, 749-754.	6.0	15
11	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	2.4	15
12	Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series. <i>International Journal of Hematology</i> , 2019, 109, 553-562.	1.6	14
13	Daratumumab for relapsed AL amyloidosis—When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review. <i>European Journal of Haematology</i> , 2021, 106, 184-195.	2.2	14
14	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	6.2	12
15	The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL—a comparative study. <i>Leukemia and Lymphoma</i> , 2018, 59, 904-910.	1.3	10
16	Prior Carpal Tunnel Syndrome and Early Concomitant Echocardiographic Findings Among Patients With Cardiac Amyloidosis. <i>Journal of Cardiac Failure</i> , 2020, 26, 909-916.	1.7	8
17	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.	7.2	8
18	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	7.2	8

#	ARTICLE	IF	CITATIONS
19	Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis. PLoS ONE, 2021, 16, e0255487.	2.5	8
20	Risk adapted post-transplant maintenance in multiple myeloma. Expert Review of Hematology, 2019, 12, 107-118.	2.2	7
21	Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e343-e348.	0.4	7
22	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplantation and Cellular Therapy, 2021, 27, 770.e1-770.e7.	1.2	6
23	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	2.4	5
24	Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma—a retrospective cohort study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2290-2299.	6.4	5
25	Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye. Leukemia and Lymphoma, 2021, 62, 1544-1553.	1.3	4
26	The Role of Autologous Stem Cell Transplantation in Amyloidosis. Oncology, 2021, 35, 471-478.	0.5	4
27	Colon perforation in multiple myeloma patients — A complication of high-dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	2.8	3
28	Should high risk smoldering myeloma be treated outside a clinical trial: NO. Leukemia and Lymphoma, 2021, 62, 2565-2567.	1.3	3
29	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639.	1.4	3
30	Agranulocytosis Associated with Waldenström Macroglobulinemia. Acta Haematologica, 2018, 140, 42-45.	1.4	2
31	Worldwide Perspectives of Amyloidosis. Acta Haematologica, 2020, 143, 301-303.	1.4	2
32	Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide. Case Reports in Transplantation, 2020, 2020, 1-4.	0.3	2
33	Outcomes of multiple myeloma patients with 17p undergoing autologous stem cell transplantation. American Journal of Hematology, 2021, 96, E35-E38.	4.1	2
34	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	1.3	2
35	Waldenstrom's macroglobulinemia in the era of immunotherapy. Leukemia and Lymphoma, 2020, 61, 1292-1304.	1.3	1
36	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	2.4	1

#	ARTICLE	IF	CITATIONS
37	Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study. <i>Leukemia Research</i> , 2021, 101, 106498.	0.8	1
38	Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Blood</i> , 2018, 132, 3295-3295.	1.4	1
39	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 22-23.	1.4	1
40	Foot drop in patients treated with bortezomib – a case series and review of the literature. <i>Leukemia and Lymphoma</i> , 2022, 63, 722-728.	1.3	1
41	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3171-3171.	1.4	1
42	Non-transplant eligible multiple myeloma: deciphering optimal first line regimens. <i>Leukemia and Lymphoma</i> , 2020, 61, 504-506.	1.3	0
43	Secondary Malignancies Following High Dose Therapy and Autologous Hematopoietic Cell Transplantation - Systematic Review and Meta Analysis. <i>Blood</i> , 2013, 122, 4633-4633.	1.4	0
44	Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study. <i>Blood</i> , 2018, 132, 5578-5578.	1.4	0
45	Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study. <i>Blood</i> , 2019, 134, 3180-3180.	1.4	0
46	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8516-8516.	1.6	0
47	Between a Rock and a Hard Place: Paraproteinemia Associated with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1488-1488.	1.4	0
48	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
49	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. <i>Blood</i> , 2020, 136, 12-13.	1.4	0
50	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
51	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.	1.4	0